OBJECTIVES: The number of clinical trials (CTs) conducted annually in Kazakhstan in recent years has been and is at a fairly low level, amounting to 1,8 CTs per 1 million population at the beginning of 2020, while in most OECD countries this indicator exceeds 30 CTs per 1 million people. In this regard, the State Health Development Program for 2020-2025 set the task of developing a set of measures to develop the CTs market in the country. The development of the CTs market at the national level has not only economic, but also high social significance.

METHODS: In order to determine the necessary measures for the development of the CTs market, we prepared a tree of problems with the identification of the causes and factors underlying the low level of CTs in the country. Then, publications (systematic analyzes, meta-analyzes and original studies) were examined on the best practices of organizing an appropriate environment for conducting CTs. Based on the analysis and taking into account th:e identified factors underlying the problem, policy options were selected.

RESULTS: Taking into account the analysis we selected the following policy options: Increasing the attractiveness of the CTs market for domestic and foreign sponsors; Creating conditions for the formation and development of the infrastructure necessary for conducting modern biomedical research and including in international CTs; Implementing effective mechanisms for involving physicians in CTs. These policy options were chosen because they are aimed at most of the factors and reasons for the underdevelopment of the CTs market in Kazakhstan.

CONCLUSIONS: Assessing the possibility of implementing the proposed policy options, taking into account the existing barriers and opportunities, we came to the conclusion that all three policy options complement each other. However more substantial achievement of the goal of development the CTs market, these policy options can give when they are combined